Pharma Business - March 5, 2015
AstraZeneca to Open R&D Site
AstraZeneca is planning to move its antibiotic research and development business into a standalone company at a cost of about $40 million. The plan will affect about 95 people at its facility in Waltham, MA. The focus of the new company will be research and development of AstraZeneca’s early-stage antibiotic pipeline. This will include AZD0914, […]